Background
==========

Improving long-term survival after liver transplantation remains a challenge, with 25% of patients dying within 5 years \[[@b1-anntransplant-23-751]\]. Reducing the toll of cardiovascular disease represents a key opportunity to increase survival rates. Cardiac events occur in 7--28% of liver transplant patients \[[@b2-anntransplant-23-751]--[@b6-anntransplant-23-751]\], depending on the definition applied, and increase mortality risk by more than 4-fold \[[@b3-anntransplant-23-751]\]. Approximately 5% of all deaths after the early post-transplant phase are accounted for by cardiovascular disease \[[@b2-anntransplant-23-751]\]. Older age \[[@b2-anntransplant-23-751],[@b5-anntransplant-23-751],[@b6-anntransplant-23-751]\], male sex \[[@b2-anntransplant-23-751],[@b3-anntransplant-23-751],[@b5-anntransplant-23-751]\], pre-transplant diabetes \[[@b2-anntransplant-23-751],[@b5-anntransplant-23-751],[@b7-anntransplant-23-751]\], pre-transplant hypertension \[[@b5-anntransplant-23-751]\], and nonalcoholic fatty liver disease as the indication for liver transplant \[[@b8-anntransplant-23-751]\] are established risk factors for cardiovascular mortality after liver transplantation.

Chronic renal dysfunction has also been shown to have a significant association with cardiovascular events in retrospective analyses \[[@b2-anntransplant-23-751],[@b4-anntransplant-23-751],[@b6-anntransplant-23-751],[@b9-anntransplant-23-751]\]. One study of data from the Organ Procurement and Transplant Network (OPTN) assessed risk factors for cardiovascular mortality in 5057 patients undergoing liver transplant for nonalcoholic steatohepatitis and found moderate or severe kidney disease (estimated GFR \[eGFR\] \<60 mL/min/1.73 m^2^) to incur a 1.8-fold increase in risk (p\<0.001) \[[@b2-anntransplant-23-751]\]. A single-center retrospective analysis of 202 primary liver transplants has reported a doubling of the risk for both cardiovascular events and cardiovascular mortality in patients with eGFR \<60 mL/min/1.73 m^2^ \[[@b6-anntransplant-23-751]\]. With 25--50% of patients showing moderate or severe renal dysfunction after liver transplantation \[[@b6-anntransplant-23-751],[@b10-anntransplant-23-751],[@b11-anntransplant-23-751]\], the impact of renal function on cardiovascular events is highly relevant. However, prospective studies of the association between renal function and cardiovascular events in liver transplant patients have hitherto been lacking.

Here, we examine the association between the evolution of renal function and the incidence of major adverse cardiac events over the first 2 years post-transplant in a post hoc analysis of data from an international, prospective, randomized trial of *de novo* liver transplant recipients \[[@b12-anntransplant-23-751],[@b13-anntransplant-23-751]\].

Material and Methods
====================

This was a post hoc analysis of the international, 24-month prospective, randomized, multicenter, 3-arm, open-label H2304 study in adult *de novo* primary liver transplant recipients (NCT00622869). The study has been described in detail elsewhere \[[@b12-anntransplant-23-751],[@b13-anntransplant-23-751]\]. In brief, patients were randomized at 30 days post-transplant to receive: (i) everolimus \[EVR\] and reduced tacrolimus \[EVR/rTAC\], (ii) EVR with tacrolimus discontinued \[TAC Elimination\], or (iii) standard tacrolimus \[TAC Control\]. Corticosteroids were administered according to local practice (minimum 5 mg prednisolone/day until at least month 6 post-transplant). Patients were required to have eGFR ≥30 mL/min/1.73 m^2^ at study entry and at the point of randomization, with urine protein excretion \<1.0 g/day.

GFR was estimated using the 4-variable Modification of Diet in Renal Disease \[MDRD4\] formula \[[@b14-anntransplant-23-751]\]:
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To evaluate trends in renal function from randomization to month 24, eGFR values documented at each study visit (months 1, 2, 3, 4, 5, 6, 9, 12, 18, and 24) were used to calculate the area under the curve (AUC), using the standard trapezoidal rule \[[@b15-anntransplant-23-751]\].

Information on major cardiac events was collected as part of the standard adverse event reporting procedures at each study visit as reported based on the investigators' judgement. Information on any major cardiac event considered to be a serious adverse event by the investigator was captured up to 30 days after the last dose of study drug. Major cardiac events were defined in accordance with MedDRA Standardized MedDRA Queries (SMQs) as ischemic heart diseases, cardiac failure, ischemic stroke, and sudden death. Thus, the following MedDRA preferred terms were included as major cardiac events: acute myocardial infarction, myocardial infarction, angina pectoris, unstable angina pectoris, cardiac failure, congestive cardiac failure, coronary artery arteriosclerosis, coronary artery disease, coronary artery insufficiency, ischemic stroke, myocardial ischemia, pulmonary edema, and sudden death.

The association between treatment group and time to occurrence of first major cardiac event was assessed by the Kaplan-Meier method. The association between eGFR AUC as a continuous variable and the occurrence of first major cardiac event was assessed using a standard Cox regression model.

All analyses were based on patients in the intent-to-treat (ITT) population, consisting of all randomized patients. Statistical analysis was performed using SAS software (version 9.3) SAS Institute Inc., Cary, NC, USA.

Results
=======

In total, 719 patients were randomized and formed the ITT population (EVR/rTAC 245, TAC Elimination 231, TAC Controls 243). The mean age was 54 years and the majority of patients were male (72.7%) ([Table 1](#t1-anntransplant-23-751){ref-type="table"}). The most frequent indications for liver transplantation were alcoholic cirrhosis (23.7%) and hepatitis C infection (24.3%). At randomization, 38.8% of patients had diabetes and 22.3% had a history of cardiac disorders, with a similar distribution of both parameters between treatment groups ([Table 1](#t1-anntransplant-23-751){ref-type="table"}). The MELD score was approximately 19 in all these treatment arms.

Treatment with statin therapy during the study was more frequent in the EVR/rTAC and TAC Elimination groups than in TAC Controls (22.0%, 21.4%, and 12.0%, respectively), and hypercholesterolemia (11.0%, 9.2%, and 3.7%) and hyperlipidemia (8.6%, 10.5% and 2.1%) were reported more frequently as adverse events ([Table 1](#t1-anntransplant-23-751){ref-type="table"}).

Data on major cardiac events were available in 716 patients (EVR/rTAC 245, TAC Elimination 229, TAC Controls 242). By month 24 post-transplant, 32 patients had experienced a first major cardiac event (32/716, 4.5%), representing an incidence of 26 events per 1000 patient years. The most frequent events were angina pectoris (n=6), cardiac failure (n=6), coronary artery disease (n=5), and cardiac failure (n=4) ([Supplementary Table 1](#s1-anntransplant-23-751){ref-type="supplementary-material"}). Major cardiac events occurred in 4.1% (10/245), 2.2% (5/229), and 7.0% (17/242) of patients in the EVR/rTAC, TAC Elimination, and TAC Control groups, respectively. [Figure 1](#f1-anntransplant-23-751){ref-type="fig"} illustrates a Kaplan-Meier analysis of the time to first occurrence of major cardiac events according to treatment group. Over the 2-year study, the lowest probability of an event was seen in the TAC Elimination group, followed by the EVR/rTAC group, with the highest probability in the TAC Control arm ([Figure 1](#f1-anntransplant-23-751){ref-type="fig"}). The difference in risk across all 3 groups was found to be significantly different (log rank p=0.043) ([Figure 1](#f1-anntransplant-23-751){ref-type="fig"}).

Renal function (eGFR) at randomization was comparable between groups (mean 81.1, 82.6, and 78.0 mL/min/1.73 m^2^ in the EVR/rTAC, TAC Elimination, and TAC Control groups, respectively; p=0.553) ([Table 1](#t1-anntransplant-23-751){ref-type="table"}). Mean eGFR at baseline was thus within 60--89 mL/min/1.73 m^2^ in both groups, representing kidney damage with mildly reduced eGFR (chronic kidney disease \[CKD\] stage 2) \[[@b16-anntransplant-23-751]\]. The proportion of patients with eGFR \<60 mL/min/1.73 m^2^ (moderate or severe CKD \[[@b16-anntransplant-23-751]\]) was 26.8%, with no marked differences between groups ([Table 1](#t1-anntransplant-23-751){ref-type="table"}). At the month 24 study visit, mean (SD) eGFR was 74.7 (26.1), 67.8 (21.0), and 77.5 (26.2) mL/min/1.73 m^2^ in the EVR/rTAC, TAC Elimination, and TAC Control groups, respectively (p=0.007).

The trajectory of eGFR over the 24-month study was assessed by calculating eGFR AUC from randomization. As shown in [Figure 2](#f2-anntransplant-23-751){ref-type="fig"}, the cumulative eGFR AUC to month 24 was highest in the TAC Elimination group (123 082 mL), slightly lower in the EVR/rTAC group (119 706 mL) and distinctly lower in the TAC Control group (105 946 mL). These values corresponded to a mean eGFR AUC of 82.4, 83.0, and 71.9 mL/min/1.73 m^2^ over the 24-month study period.

Cox regression modeling showed that that the mean eGFR AUC from randomization to month 24 post-transplant was inversely associated with the time to first occurrence of a major cardiac event: the hazard ratio per mL/min/1.73 m^2^ was −0.0000015 \[95% CI--0.00000078; −0.0000024\] (p\<0.001).

Discussion
==========

Analysis of this large dataset from a prospective, randomized trial with protocol-defined monitoring of renal function and adverse events confirms retrospective observations \[[@b2-anntransplant-23-751],[@b4-anntransplant-23-751],[@b6-anntransplant-23-751],[@b9-anntransplant-23-751]\] that the risk of major cardiac events is inversely associated with renal function, as assessed by eGFR AUC, over the first 2 years after liver transplantation.

There is convincing evidence from large studies in non-transplant populations that renal dysfunction (eGFR \<60 mL/min/1.73 m^2^) is significantly associated with a higher risk for major cardiac events \[[@b17-anntransplant-23-751]\] and cardiovascular mortality \[[@b18-anntransplant-23-751]\]. One study observed a 32% increased risk for myocardial infarction with each 10 mL/min/1.73 m^2^ decrease in eGFR \[[@b19-anntransplant-23-751]\]. A number of uremic-specific cardiovascular risk factors have been identified in the general population, including anemia, hyperparathyroidism, hyperhomocysteinemia, high lipoprotein(a) levels, and low vitamin C \[[@b20-anntransplant-23-751]\], which would be expected to apply equally in liver transplant recipients with poor renal function. Additionally, transplant recipients are subject to chronic renal insults associated with long-term immunosuppression, most prominently dose-dependent nephrotoxicity associated with calcineurin inhibitors (CNIs) \[[@b21-anntransplant-23-751]\]. In the present 2-year study, patients receiving everolimus with reduced or discontinued tacrolimus had better renal function than the TAC Control group, as demonstrated by higher eGFR AUC values. This is consistent with the findings of 2 previous randomized trials in liver transplantation \[[@b22-anntransplant-23-751],[@b23-anntransplant-23-751]\], including the PROTECT study \[[@b24-anntransplant-23-751]\], in which early introduction of everolimus with CNI withdrawal resulted in higher mean eGFR. Notably, both the EVR/rTAC and TAC Elimination groups were associated with a significant reduction in risk for major cardiac events versus standard CNI therapy based on Kaplan-Meier analysis, but with a more marked effect in the TAC Elimination group. This observation supports the premise that cardiac events become more likely as renal function deteriorates. Other randomized studies of everolimus with CNI withdrawal in liver transplantation, including the PROTECT study \[[@b22-anntransplant-23-751],[@b24-anntransplant-23-751]\], have not described the incidence of major cardiac events \[[@b22-anntransplant-23-751]--[@b24-anntransplant-23-751]\], but in renal transplantation the recent ELEVATE study reported that early conversion from CNI therapy to everolimus was associated with a significant reduction in such events at 12 months post-transplant \[[@b25-anntransplant-23-751]\].

The question arises whether other effects of mTOR inhibition contributed to the reduced rate of major cardiac events in the everolimus-treated cohorts, in addition to improved renal function. A significant direct cardioprotective effect seems unlikely. Despite evidence that switching to a mammalian target of rapamycin (mTOR) inhibitor reduces left ventricular remodeling after heart transplantation \[[@b26-anntransplant-23-751],[@b27-anntransplant-23-751]\], early conversion to everolimus has not been found to exert a clinically relevant effect on ventricular mass in kidney transplantation \[[@b25-anntransplant-23-751],[@b28-anntransplant-23-751]\]. Studies have shown mixed results concerning improved blood pressure after switching to everolimus from CNI \[[@b25-anntransplant-23-751],[@b28-anntransplant-23-751]\], while data suggesting a beneficial effect on arterial stiffness \[[@b29-anntransplant-23-751],[@b30-anntransplant-23-751]\] was not borne out in the recent ELEVATE trial \[[@b25-anntransplant-23-751]\]. The immunomodulatory effects of everolimus may attenuate the process of atherosclerosis, based on studies in heart transplant recipients \[[@b31-anntransplant-23-751],[@b32-anntransplant-23-751]\], which would contribute to a lower risk for cardiac events. Interestingly, the reduced risk for major cardiac events in the everolimus-treated cohorts was observed despite the known hyperlipidemic effect of mTOR inhibitors \[[@b33-anntransplant-23-751], [@b34-anntransplant-23-751]\] which was again apparent in the present cohort of patients, indicating that any adverse risk associated with this hyperlipidemic influence is outweighed by other effects.

This analysis was undertaken post hoc but benefitted from prospective collection of data on eGFR and adverse events over the first 2 years after liver transplantation in a large cohort of patients. The study population had similar mean baseline eGFR values to the general liver transplant population \[[@b35-anntransplant-23-751]\]. Patients with severe renal dysfunction (\<30 mL/min/1.73 m^2^, i.e., CKD stage 4 or 5) were excluded, and the results are not necessarily applicable in that context, but such patients represent a relatively small proportion of recipients. It should be noted that although the randomized PROTECT study found no increase in biopsy-proven acute rejection when CNI elimination was performed more gradually and basiliximab induction was given \[[@b22-anntransplant-23-751]\], continuation of a reduced-exposure CNI regimen after introducing everolimus may overall be a more appropriate option than CNI withdrawal \[[@b12-anntransplant-23-751]\].

Conclusions
===========

These findings confirm retrospective evidence that the risk of major cardiac events increases with deteriorating renal function after liver transplantation. In view of the risk of cirrhotic cardiomyopathy and prevalence of conventional cardiovascular risk factors in liver transplant candidates, the European Association for the Study of the Liver (EASL) recommends that all candidates should undergo cardiovascular screening \[[@b36-anntransplant-23-751]\]. EASL advises routine assessment with an electrocardiogram and transthoracic echocardiography, with stress echocardiograms reserved for high-risk cases (i.e., more than 2 risk factors or if the patient is \>50 years old) \[[@b36-anntransplant-23-751]\]. The present results underscore the importance of such screening procedures and highlight that particularly careful cardiovascular risk management is advisable in liver transplant patients with renal impairment. Furthermore, the analysis demonstrates that an immunosuppressive regimen based on everolimus with tacrolimus withdrawal, or to a lesser extent tacrolimus reduction, improves both renal function and the risk of major cardiac events compared to standard treatment with tacrolimus. Selection of an everolimus-based immunosuppressive regimen may be advantageous in avoiding major cardiac events in liver transplant recipients with renal dysfunction.

Supplementary Table
===================

###### 

First major adverse cardiac events to month 24, by MedDRA preferred term, according to treatment group (ITT population).

                                     EVR/rTAC N=245   TAC Elimination N=231   TAC Control N=243
  ---------------------------------- ---------------- ----------------------- -------------------
  Acute myocardial infarction        1                0                       2
  Angina pectoris                    1                1                       4
  Angina unstable                    1                0                       0
  Cardiac failure                    2                0                       4
  Cardiac failure congestive         0                1                       1
  Coronary artery arteriosclerosis   1                0                       0
  Coronary artery disease            2                0                       3
  Coronary artery insufficiency      0                1                       0
  Ischemic stroke                    0                0                       1
  Myocardial infarction              0                1                       0
  Myocardial ischemia                1                0                       1
  Pulmonary edema                    1                0                       0
  Sudden death                       0                1                       1
  **Total**                          **10**           **5**                   **17**
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![Kaplan-Meier (KM) plot of major cardiac events (MACE) to month 24 according to treatment group (ITT population). EVR -- everolimus; rTAC -- reduced tacrolimus; TAC -- tacrolimus.](anntransplant-23-751-g001){#f1-anntransplant-23-751}

![Area under the curve (AUC) of estimated GFR (eGFR) from baseline to month 24 according to treatment group (ITT population). EVR -- everolimus; rTAC -- reduced tacrolimus; TAC -- tacrolimus.](anntransplant-23-751-g002){#f2-anntransplant-23-751}

###### 

Population characteristics at randomization by treatment group (ITT population).

                                                                    EVR/rTAC N=245   TAC Elimination N=231   TAC Control N=243
  ----------------------------------------------------------------- ---------------- ----------------------- -------------------
  Age (years)                                                       53.6 (9.2)       53.2 (10.8)             54.5 (8.7)
  Male sex, n (%)                                                   180 (73.5)       164 (71.0)              179 (73.7)
  Body mass index (kg/m^2^)                                         25.1 (4.2)       25.3 (4.3)              24.5 (4.2)
  Diabetes, n (%)                                                   95 (38.8)        83 (35.9)               101 (41.6)
  Primary disease leading to liver transplantation, n (%)                                                    
   Alcoholic cirrhosis                                              71 (29.0)        49 (21.2)               51 (21.0)
   Hepatitis C                                                      62 (25.3)        56 (24.2)               57 (23.5)
   Hepatocellular carcinoma                                         42 (17.1)        31 (13.4)               35 (14.4)
   Hepatitis B                                                      17 (6.9)         17 (7.4)                15 (6.2)
   Other                                                            53 (21.6)        78 (33.8)               85 (35.0)
  MELD score[\*](#tfn1-anntransplant-23-751){ref-type="table-fn"}   19.2 (9.0)       19.6 (7.5)              19.0 (7.6)
  eGFR, mL/min/1.73 m^2^                                            81.1 (32.6)      82.6 (37.2)             78.0 (27.5)
  eGFR \<60mL/min/1.73 m^2^ (%)                                     71 (29.0)        61 (26.4)               61 (25.1)
  Medical history of cardiac disorders, n (%)                       58 (23.7)        49 (21.2)               53 (21.8)
   Mitral valve incompetence                                        7 (2.9)          9 (3.9)                 9 (3.7)
   Tricuspid valve incompetence                                     7 (2.9)          4 (1.7)                 4 (1.6)
   Left ventricular hypertrophy                                     8 (3.3)          8 (3.5)                 0
   Coronary artery disease                                          6 (2.4)          5 (2.2)                 10 (4.1)
   Atrial fibrillation                                              5 (2.0)          4 (1.7)                 5 (2.1)

Based on laboratory values only.

Continuous variables are shown as mean (SD). eGFR -- estimated GFR (calculated by abbreviated Modification of Diet in Renal Disease \[MDRD4\] equation; EVR -- everolimus; MELD -- Model for End-stage Liver Disease; TAC -- tacrolimus.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
